Recent Studies Validate High performance and Accurate Results for UltraMAB®OTI1A4 as an Effective Screening Tool for ALK Translocation in Non-Small Cell Lung Cancer patients.

Rockville, MD – April 14, 2016. A pair of recently published studies shed light on the highly interesting area on detection of ALK expression among NSCLC patients by IHC. One study was conducted by NordiQC (Aalborg, Denmark), the other by a group of Germany scientists and was published in the Journal of Thoracic Oncology. Both studies compared the performance of OTI1A4 antibody from OriGene (Rockville, MD) and the D5F3 antibody from Ventana (Tucson, AZ) in a large set of lung cancer specimens with known ALK status identified by FISH assay.

weiterlesen...